Compare JPMorgan Equity Premium Income ETF (JEPI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Merck & Co., Inc. — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.79 (market cap $45.55B), while Merck & Co., Inc. trades at $146.06 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 7.7× JPMorgan Equity Premium Income ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while JPMorgan Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 57 Days and Merck & Co., Inc. for 98 Days on average.
| JEPI | MRK | |
|---|---|---|
Market Cap | $45.55B | $351.28B |
Volume | 3,820,809 | 7,969,665 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $156.43 |
52-Week Low | $55.29 | $82.49 |
Typical Hold Time | 57 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.79, up 0.6% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators and key support at $56. Recent dividend activity includes three distributions averaging $0.36 per share through August-October 2026. Media coverage focuses on income generation strategies and tax implications for retirement portfolios.
The covered-call strategy provides consistent income but may limit upside during market rallies. Institutional interest remains strong with recent position increases. Key risks include interest rate sensitivity and the trade-off between yield and capital appreciation potential in rising markets.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
